Skip to main content
Premium Trial:

Request an Annual Quote

Miraculins Passes ISO Certification Audit

NEW YORK (GenomeWeb News) – Miraculins today said that it has successfully completed a two-part ISO certification audit conducted by the BSI Group.

The Winnipeg, Manitoba-based biomarker-based diagnostics firm said that the audit recommended that the firm receive ISO 13485 certification. The company said the certification is a "critical regulatory and business plan milestone" as heads toward commercial launch of its PreVu Non-Invasive Skin Cholesterol test.

"Upon receipt of our ISO Certificate we will complete the required Health Canada and FDA filings, and the CE Mark Registration for the European Union and proceed to make PreVu commercially available to health care professionals and patients in North America and overseas in the very near term," Christopher Moreau, president and CEO of Miraculins, said in a statement.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.